The meeting has been organized as 8 sessions that will address these goals. Talks will cover the importance of the gut-liver axis in relevant areas of Hepatology, including advanced cirrhosis, and liver disease secondary to alcohol, fat deposition or autoimmunity. Emerging areas such as the influence of gut microbiota on drug metabolism and on hepatobiliary malignancies will also be covered. Further, the conference will specifically examine therapies designed to modify the components of the gut-liver axis, such as bile acid signaling, fecal transplantation, adsorbent carbons, and pro- and antibiotics, among others.
The conference will be a forum of interest, discussion and information for both clinical hepatologists and basic and translational researchers. In line with other recent EASL events, we will count on the active participation of partners from industry. Sessions will include presentations by eminent scientists on evidence-based translational research from academia and industry. We hope the conference will act as a platform to facilitate interaction and research networking among academia, industry and the scientific audience. In this regard, active researchers in this field will have the chance to submit data from ongoing projects that will be presented as e-posters.
We envisage this meeting on the gut-liver axis as a cutting edge forum of interest for clinicians, basic and translational researchers and industry in this emerging area of hepatology.
We look forward to welcoming and meeting you in Leuven for this major EASL event
The Scientific Committee
Agustín Albillos, Spain

Andrea De Gottardi, Switzerland

Maria Rescigno, Italy